Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial
Research output: Contribution to journal › Journal article › Research › peer-review
Dorien Reijnders, Gijs H Goossens, Gerben D A Hermes, Evelien P J G Neis, Christina M van der Beek, Jasper Most, Jens J Holst, Kaatje Lenaerts, Ruud S Kootte, Max Nieuwdorp, Albert K Groen, Steven W M Olde Damink, Mark V Boekschoten, Hauke Smidt, Erwin G Zoetendal, Cornelis H C Dejong, Ellen E Blaak
The gut microbiota has been implicated in obesity and cardiometabolic diseases, although evidence in humans is scarce. We investigated how gut microbiota manipulation by antibiotics (7-day administration of amoxicillin, vancomycin, or placebo) affects host metabolism in 57 obese, prediabetic men. Vancomycin, but not amoxicillin, decreased bacterial diversity and reduced Firmicutes involved in short-chain fatty acid and bile acid metabolism, concomitant with altered plasma and/or fecal metabolite concentrations. Adipose tissue gene expression of oxidative pathways was upregulated by antibiotics, whereas immune-related pathways were downregulated by vancomycin. Antibiotics did not affect tissue-specific insulin sensitivity, energy/substrate metabolism, postprandial hormones and metabolites, systemic inflammation, gut permeability, and adipocyte size. Importantly, energy harvest, adipocyte size, and whole-body insulin sensitivity were not altered at 8-week follow-up, despite a still considerably altered microbial composition, indicating that interference with adult microbiota by 7-day antibiotic treatment has no clinically relevant impact on metabolic health in obese humans.
|Number of pages||12|
|Publication status||Published - 12 Jul 2016|
- Journal Article